Search Result

Isoforms Recommended:	mTORC1

Results for "

mTORC1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (6) Aminoacyl-tRNA Synthetase (3) AMPK (8) Annexin A (1) Antibiotic (7) Antifolate (1) Apoptosis (30) Atg8/LC3 (3) ATP Citrate Lyase (2) Autophagy (56) Bacterial (12) c-Fms (1) c-Met/HGFR (3) Caspase (1) DNA-PK (9) DNA/RNA Synthesis (6) Drug Intermediate (1) Drug Metabolite (2) EGFR (1) Endogenous Metabolite (9) Environmental Pollutants (1) ERK (4) Farnesyl Transferase (1) FBPase (1) Ferroptosis (2) FGFR (1) FKBP (7) Fructose-1,6-bisphosphate aldolase (1) Fungal (8) GLUT (1) Glutaminase (3) HIF/HIF Prolyl-Hydroxylase (1) HIV (1) iGluR (3) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (5) Isotope-Labeled Compounds (7) Keap1-Nrf2 (2) Kinesin (1) LDLR (1) MetAP (1) Microsomal Triglyceride Transfer Protein (MTP) (1) Mitophagy (2) mTOR (116) NAMPT (2) NF-κB (2) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (2) p62 (3) Parasite (1) PD-1/PD-L1 (1) Phosphatase (1) PI3K (23) PI5P4K (1) Pim (1) PKC (1) Prolyl Endopeptidase (PREP) (3) Proton Pump (1) RABV (1) Reference Standards (23) Ribosomal S6 Kinase (RSK) (8) ROR (1) Small Interfering RNA (siRNA) (2) Stearoyl-CoA Desaturase (SCD) (1) TGF-beta/Smad (1) Tyrosinase (3) ULK (1) VEGFR (1)
By Research Areas:	Cancer (131) Cardiovascular Disease (4) Endocrinology (1) Infection (14) Inflammation/Immunology (14) Metabolic Disease (20) Neurological Disease (17)
Click Chemistry:	Azide (1)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

148

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10219

Rapamycin Maximum Cited Publications 1338 Publications Verification Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-13003

Torin 1 120+ Cited Publications	mTOR Autophagy	Cancer
Torin 1 is a potent inhibitor of *mTOR* with an IC₅₀ of 3 nM. Torin 1 inhibits both *mTORC1/2 complexes with IC₅₀* values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.

HY-10422

AZD-8055 65+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive *mTOR* kinase inhibitor with an IC₅₀ of 0.8 nM. AZD-8055 inhibits both *mTORC1* and *mTORC2* ^[1].

HY-N0112

Dihydromyricetin 20+ Cited Publications Ampelopsin; Ampeloptin	mTOR Influenza Virus DNA/RNA Synthesis Autophagy	Infection Cancer
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-10681

Gedatolisib 5 Publications Verification PKI-587; PF-05212384	PI3K mTOR	Cancer
Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and *mTOR* with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively ^[1]. Gedatolisib is equally effective in both complexes of mTOR, *mTORC1* and *mTORC2* .

HY-13002

Torin 2 15+ Cited Publications	mTOR DNA-PK Autophagy Apoptosis	Cancer
Torin 2 is an *mTOR* inhibitor with EC₅₀ of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC₅₀: 200 nM). Torin 2 also inhibits DNA-PK with an IC₅₀ of 0.5 nM in the cell free assay. Torin 2 can suppress both *mTORC1* and *mTORC2*.

HY-15247

Vistusertib 30+ Cited Publications AZD2014	mTOR Autophagy Apoptosis	Cancer
Vistusertib (AZD2014) is an ATP competitive *mTOR* inhibitor with an IC₅₀ of 2.81 nM. AZD2014 inhibits both *mTORC1* and *mTORC2* complexes.

HY-W015309

Decanoic acid 4 Publications Verification	Environmental Pollutants Endogenous Metabolite iGluR Glutaminase c-Met/HGFR Tyrosinase	Neurological Disease Metabolic Disease Cancer
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy ^[1] .

HY-114384

Mefluleucine 5+ Cited Publications NV-5138	mTOR	Neurological Disease
Mefluleucine (NV-5138), a leucine analog, is the first selective and orally active brain *mTORC1* activator, binding to Sestrin2. Mefluleucine is used for antidepressant studies ^[1] .

HY-10474

Torkinib 25+ Cited Publications PP 242	mTOR Autophagy Mitophagy Apoptosis	Cancer
Torkinib (PP 242) is a selective and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 8 nM ^[1]. PP242 inhibits both *mTORC1* and *mTORC2* with IC₅₀s of 30 nM and 58 nM, respectively .

HY-128892

EN6 5 Publications Verification	Autophagy	Neurological Disease
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the *ATP6V1A* subunit of the lysosomal v-ATPase. EN6-mediated modification of *ATP6V1A* uncouples v-ATPase from Rag, leading to inhibition of *mTORC1* signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner ^[1].

HY-16962

CC-115 2 Publications Verification	DNA-PK mTOR	Cancer
CC-115 is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both *mTORC1* and *mTORC2* signaling.

HY-14668

Lomitapide mesylate 5+ Cited Publications AEGR-733 mesylate; BMS-201038 mesylate	Microsomal Triglyceride Transfer Protein (MTP) mTOR LDLR Autophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective *mTORC1* inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits *mTORC1* in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8 ⁺ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia ^[1] .

HY-10423

OSI-027 10+ Cited Publications ASP7486	mTOR Autophagy	Cancer
OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive *mTOR* kinase activity inhibitor with an IC₅₀ of 4 nM. OSI-027 targets both *mTORC1* and *mTORC2* with IC₅₀s of 22 nM and 65 nM, respectively ^[1] .

HY-124798

Rheb inhibitor NR1 3 Publications Verification	mTOR	Neurological Disease Inflammation/Immunology Cancer
Rheb inhibitor NR1 is a Rheb inhibitor with an IC₅₀ of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven ^T389pS6K1 and increases the phosphorylation of ^S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity ^[1]. ^{(Rheb-IVK: Rheb-dependent mTORC1 kinase activity)}

HY-16956

Onatasertib 3 Publications Verification CC-223; ATG-008	mTOR Apoptosis	Cancer
Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of *mTOR* kinase, with an IC₅₀ value for mTOR kinase of 16 nM. Onatasertib inhibits both *mTORC1* and *mTORC2*.

HY-12513

Samotolisib 5+ Cited Publications LY3023414	PI3K DNA-PK mTOR Autophagy	Cancer
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and *mTORC1/2* with IC₅₀s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits *mTORC1*/2 at low nanomolar concentrations ^[1] .

HY-134904

RMC-6272 3 Publications Verification RM-006	mTOR	Cancer
RMC-6272 (RM-006) is a bi-steric *mTORC1*-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors ^[1].

HY-132168

RMC-5552 5 Publications Verification	mTOR	Cancer
RMC-5552 is a potent and selective *mTORC1* inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and *p4EBP1* with IC₅₀s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC₅₀ of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity ^[1].

HY-50710

KU-0063794 10+ Cited Publications	mTOR	Cancer
KU-0063794 is a potent and specific *mTOR* inhibitor, inhibiting both the *mTORC1* and *mTORC2* complexes with IC₅₀s of 10 nM.

HY-15174

Dactolisib Tosylate 65+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and *mTOR* kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits *mTORC1* and *mTORC2*.

HY-126077

MTI-31 1 Publications Verification LXI-15029	mTOR	Inflammation/Immunology Cancer
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of *mTORC1* and *mTORC2. MTI-31 is selective for mTOR* (K_d: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC₅₀ of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer ^[1].

HY-14530

Pelitrexol 2 Publications Verification AG 2037	Antifolate	Cancer
Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), a purine biosynthetic enzyme. Pelitrexol also inhibits *mTORC1* by reducing GTP-bound Rheb level, a *mTORC1* obligate activator. Pelitrexol shows robust tumor growth suppression in mice ^[1].

HY-100026

PQR620 4 Publications Verification	mTOR	Cancer
PQR620 is an orally bioavailable and selective brain penetrant inhibitor of *mTORC1/2* ^[1].

HY-13806

XL388 4 Publications Verification	mTOR Autophagy	Cancer
XL388 is a highly potent and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 9.9 nM. XL388 simultaneously inhibits both *mTORC1* and *mTORC2*.

HY-10044

WYE-132 4 Publications Verification WYE-125132	mTOR Apoptosis	Cancer
WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific *mTOR* kinase inhibitor (IC₅₀: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits *mTORC1* and *mTORC2*.

HY-10219S

Rapamycin-d3 1 Publications Verification Sirolimus-d₃; AY-22989-d₃; NSC 226080-d₃	Isotope-Labeled Compounds mTOR FKBP Autophagy	Cancer
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1. Rapamycin is an autophagy* activator, an immunosuppressant ^[1] .

HY-10219R

Rapamycin (Standard) Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)	Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-100222

CZ415 4 Publications Verification	mTOR	Cancer
CZ415 is a potent and highly selective *mTOR* inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits *mTORC1* and *mTORC2* protein complex.

HY-15248

GDC-0349 2 Publications Verification	mTOR Autophagy	Cancer
GDC-0349 is a potent and selective ATP-competitive *mTOR* inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both *mTORC1* and *mTORC2* complexes.

HY-114384B

Mefluleucine hydrochloride 5+ Cited Publications NV-5138 hydrochloride	mTOR	Neurological Disease
Mefluleucine (NV-513) hydrochloride, a leucine analog, is the first selective and orally active brain *mTORC1* activator, binding to Sestrin2. Mefluleucine hydrochloride is used for antidepressant studies ^[1] .

HY-16962A

CC-115 hydrochloride 2 Publications Verification	DNA-PK mTOR	Cancer
CC-115 hydrochloride is a potent and dual DNA-PK and *mTOR* kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both *mTORC1* and *mTORC2* signaling.

HY-15880

CCT007093 2 Publications Verification	Phosphatase Apoptosis Autophagy	Cancer
CCT007093 is an effective protein phosphatase 1D (PPM1D Wip1) inhibitor. Wip1 inhibition can activate the mTORC1 pathway and enhance hepatocyte proliferation after hepatectomy ^[1] .

HY-12034

WYE-354 5+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
WYE-354 is an ATP-competitive *mTOR* inhibitor with an IC₅₀ of 5 nM. WYE-354 also inhibits PI3Kα and PI3Kγ with IC₅₀s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both *mTORC1* and *mTORC2*. WYE-354 induces autophagy activation in vitro .

HY-14581

Palomid 529 4 Publications Verification P529	mTOR Apoptosis	Cancer
Palomid 529 is a potent inhibitor of *mTORC1* and *mTORC2* complexes.

HY-143510

RMC-4627	mTOR	Cancer
RMC-4627 is a selective *mTORC1* inhibitor that activates 4EBP1 and inhibits tumor growth.

HY-B1787

Sulindac sulfone	mTOR Drug Metabolite	Cancer
Sulindac sulfone is an *mTORC1* pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research ^[1].

HY-18353

mTOR inhibitor-3 3 Publications Verification	mTOR	Cancer
mTOR inhibitor-3 is a remarkably selective *mTOR* inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses *mTORC1* and *mTORC2* in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

HY-15272

WAY-600 5+ Cited Publications	mTOR	Inflammation/Immunology Cancer
WAY-600 is a potent, ATP-competitive, and selective *mTOR* inhibitor with an IC₅₀ of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.

HY-108900

Leu-AMS	Aminoacyl-tRNA Synthetase Bacterial	Infection Cancer
Leu-AMS (compound 6), a leucine analogue, is a potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC₅₀ of 22.34 nM, which inhibits the catalytic activity of LRS but did not affect the leucine-induced mTORC1 activation. Leu-AMS shows cytotoxicity in cancer cells and normal cells, and inhibits the growth of bacteria ^[1].

HY-107365

PQR530	PI3K mTOR	Cancer
PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, with a subnanomolar K_d toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity ^[1] .

HY-153789

PI5P4Kγ-IN-1	PI5P4K mTOR	Cancer
PI5P4Kγ-IN-1 is an ATP-competitive, highly selective chemical probe for PI5P4Kγ, with a K_d of 19 nM and an IC₅₀ of 67 nM. PI5P4Kγ-IN-1 effectively inhibits PI5P4Kγ function and activates the *mTORC1* signaling pathway in cells. PI5P4Kγ-IN-1 can be used in studies related to diseases such as breast cancer ^[1].

HY-15271

WYE-687 3 Publications Verification	mTOR PI3K	Cancer
WYE-687 is an ATP-competitive *mTOR* inhibitor with an IC₅₀ of 7 nM. WYE-687 concurrently inhibits activation of *mTORC1* and *mTORC2. WYE-687 also inhibits PI3Kα* and PI3Kγ with IC₅₀s of 81 nM and 3.11 μM, respectively.

HY-10219S1

Rapamycin-13C,d3 Sirolimus-¹³C,d₃; AY-22989-¹³C,d₃ NSC 226080-¹³C,d₃	Isotope-Labeled Compounds mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) ^[1]. Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1. Rapamycin is an autophagy* activator, an immunosuppressant ^[1] .

HY-10219G

Rapamycin Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Infection Cancer
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-N2517

Dihydroevocarpine	mTOR	Cancer
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the *mTORC1/2* activity ^[1].

HY-W058849

MT 63-78	AMPK mTOR Apoptosis	Cancer
MT 63-78 is a specific and potent direct AMPK activator with an EC₅₀ of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and *mTORC1* pathways. MT 63-78 has antitumor effects ^[1].

HY-128340

Autogramin-2	Autophagy	Cancer
Autogramin-2 potently inhibits autophagy induced by either starvation (IC₅₀=0.27 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.14 μM) ^[1].

HY-128339

Autogramin-1	Autophagy	Cancer
Autogramin-1 potently inhibits autophagy induced by either starvation (IC₅₀=0.17 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.44 μM) ^[1].

HY-125355

SEC 1 Publications Verification	Apoptosis Annexin A	Cancer
SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation ^[1] .

Cat. No.	Product Name	Type

HY-10219G

Rapamycin

Sirolimus; AY-22989; NSC 226080

Fluorescent Dye

Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219GL

Rapamycin (GMP Like)

Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

Fluorescent Dye

Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

Cat. No.	Product Name	Type

HY-W338584

Hydroxycitric acid tripotassium

1 Publications Verification

Biochemical Assay Reagents

Tripotassium hydroxycitrate is an orally active, multi-target, multi-bioactive organic acid. Tripotassium hydroxycitrate activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Tripotassium hydroxycitrate activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Tripotassium hydroxycitrate activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation ^[1] .

HY-10219G

Rapamycin

Sirolimus; AY-22989; NSC 226080

Biochemical Assay Reagents

HY-10219GL

Rapamycin (GMP Like)

Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P2657

Verucopeptin	HIF/HIF Prolyl-Hydroxylase Proton Pump Endogenous Metabolite	Cancer
Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.

HY-P11162

FGF7p	FGFR Akt ERK mTOR Apoptosis	Inflammation/Immunology
FGF7p is a small molecule peptide and a potential bladder protector. FGF7p can activate downstream signaling pathways of FGFR2 in the urinary tract epithelium (pFRS2α, pAKT and pERK). FGF7p alleviates cyclophosphamide induced apoptosis and tissue damage in urinary tract epithelial cells by activating AKT and its downstream anti apoptotic targets (pBAD, pS6/mTORC1). FGF7p is commonly used in the study of inflammatory conditions ^[1].

HY-P5984

Thioether-cyclized helix B peptide, CHBP	mTOR	Others
Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 ^[1].

HY-P5984A

Thioether-cyclized helix B peptide, CHBP TFA	mTOR	Others
Thioether-cyclized helix B peptide, CHBP (TFA) is the TFA form of Thioether-cyclized helix B peptide, CHBP (HY-P5984). Thioether-cyclized helix B peptide, CHBP (TFA) can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10219

Rapamycin Maximum Cited Publications 1338 Publications Verification Sirolimus; AY-22989; NSC 226080	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Disease Research Disease Research Fields Source Classification Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-N0112

Dihydromyricetin 20+ Cited Publications Ampelopsin; Ampeloptin	Infection Flavanonols Structural Classification Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	mTOR Influenza Virus DNA/RNA Synthesis Autophagy
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-18980

Rottlerin 20+ Cited Publications Mallotoxin; NSC 56346; NSC 94525	Structural Classification Chalcones Flavonoids Classification of Application Fields Phenols Polyphenols Euphorbiaceae Plants Disease Research Fields Mallotus philippensis Source Classification Cancer	PKC Autophagy Apoptosis HIV RABV
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation ^[1] . Rottlerin inhibits *HIV-1* integration and Rabies virus (RABV) infection .

HY-W015309

Decanoic acid 4 Publications Verification	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Biological Pesticide Research Source Classification Agricultural Research	Environmental Pollutants Endogenous Metabolite iGluR Glutaminase c-Met/HGFR Tyrosinase
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy ^[1] .

HY-N1437

Hydroxycitric acid 1 Publications Verification	Structural Classification Ketones, Aldehydes, Acids Guttiferae Plants Garcinia gummi-gutta (L.) Roxb. Source Classification	Apoptosis Ferroptosis mTOR DNA/RNA Synthesis Keap1-Nrf2 Ribosomal S6 Kinase (RSK) NF-κB ATP Citrate Lyase AMPK
Hydroxycitric acid is an orally active, multi-target, multi-bioactive organic acid. activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Hydroxycitric acid activates the *Nrf2/Keap1* and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Hydroxycitric acid activates both the AMPK and *mTORC1/S6K* pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation ^[1] .

HY-N0656A

(+)-Usnic acid 2 Publications Verification	other families Classification of Application Fields Ketones, Aldehydes, Acids Plants Lichen Disease Research Fields Cancer	mTOR Bacterial Autophagy
(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of *mTOR, and inhibits mTORC1/2* activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer and anti-inflammatory activity. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium ^[1] .

HY-10219R

Rapamycin (Standard) Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Disease Research Endogenous metabolite Source Classification	Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-N1677

2,6-Dimethoxy-1,4-benzoquinone	Infection Quinones other families Classification of Application Fields Metabolic Disease Benzene Quinones Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Akt mTOR Bacterial Fungal AMPK
2,6-Dimethoxy-1,4-benzoquinone is a 1,4-benzoquinone derivative. 2,6-Dimethoxy-1,4-benzoquinone promotes phosphorylation of AKT, S6K, *mTOR, 4E-BP1, and AMPK, and attenuates mTORC1* activity as part of the *AKT/mTOR* pathway. 2,6-Dimethoxy-1,4-benzoquinone stimulates myoblast differentiation, increases myotube size, elevates MHC protein expression, enhances mitochondrial biogenesis, respiration, and DNA content, and increases skeletal muscle weights, fiber size, grip strength, and treadmill performance. 2,6-Dimethoxy-1,4-benzoquinone exerts anti-cancer, anti-inflammatory, anti-adipogenic, antibacterial, and antimutagenic effects, inhibits adipogenic transcription factors, nitric oxide production, skin tumor development, Magnaporthe oryzae growth, spore germination, appressorium formation, and growth of select bacterial species, induces H₂O₂ generation and rice defense gene expression, and reduces rice blast lesion formation. 2,6-Dimethoxy-1,4-benzoquinone can be used for the research of obesity, skin tumorigenesis, rice blast disease, and food-borne illness ^[1] .

HY-N2517

Dihydroevocarpine	Alkaloids Classification of Application Fields Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer Source Classification	mTOR
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the *mTORC1/2* activity ^[1].

HY-N0112R

Dihydromyricetin (Standard) Ampelopsin (Standard); Ampeloptin (Standard)	Flavanonols Structural Classification Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards mTOR Influenza Virus DNA/RNA Synthesis Autophagy
Dihydromyricetin (Standard) is the analytical standard of Dihydromyricetin. This product is intended for research and analytical applications. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-N3628

Coronarin A	Hedychium coronarium Koen. Structural Classification Terpenoids Diterpenoids Plants Zingiberaceae	mTOR Ribosomal S6 Kinase (RSK)
Coronarin A is an orally active natural compound that inhibits *mTORC1* and *S6K1* to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research ^[1].

HY-W015309R

Decanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy ^[1] .

HY-N0656AR

(+)-Usnic acid (Standard)	Structural Classification other families Ketones, Aldehydes, Acids Plants Lichen	Reference Standards mTOR Bacterial Autophagy
(+)-Usnic acid (Standard) is the analytical standard of (+)-Usnic acid. This product is intended for research and analytical applications. (+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity ^[1]. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium .

HY-N1677R

2,6-Dimethoxy-1,4-benzoquinone (Standard)	Quinones other families Benzene Quinones Plants Endogenous metabolite Source Classification	Reference Standards Akt mTOR Bacterial Fungal AMPK
2,6-Dimethoxy-1,4-benzoquinone (Standard) is the analytical standard of 2,6-Dimethoxy-1,4-benzoquinone (HY-N1677). This product is intended for research and analytical applications. 2,6-Dimethoxy-1,4-benzoquinone is a 1,4-benzoquinone derivative. 2,6-Dimethoxy-1,4-benzoquinone promotes phosphorylation of AKT, S6K, mTOR, 4E-BP1, and AMPK, and attenuates mTORC1 activity as part of the AKT/mTOR pathway. 2,6-Dimethoxy-1,4-benzoquinone stimulates myoblast differentiation, increases myotube size, elevates MHC protein expression, enhances mitochondrial biogenesis, respiration, and DNA content, and increases skeletal muscle weights, fiber size, grip strength, and treadmill performance. 2,6-Dimethoxy-1,4-benzoquinone exerts anti-cancer, anti-inflammatory, anti-adipogenic, antibacterial, and antimutagenic effects, inhibits adipogenic transcription factors, nitric oxide production, skin tumor development, Magnaporthe oryzae growth, spore germination, appressorium formation, and growth of select bacterial species, induces H2O2 generation and rice defense gene expression, and reduces rice blast lesion formation. 2,6-Dimethoxy-1,4-benzoquinone can be used for the research of obesity, skin tumorigenesis, rice blast disease, and food-borne illness.

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3 1 Publications Verification
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1. Rapamycin is an autophagy* activator, an immunosuppressant ^[1] .

HY-10219S1

Rapamycin-13C,d3
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) ^[1]. Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1. Rapamycin is an autophagy* activator, an immunosuppressant ^[1] .

HY-W266188

Decanoic acid-13C

Decanoic acid- ¹³C is the ¹³C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy ^[1] .

HY-W742805

Sulindac Sulfone-d6
Sulindac Sulfone-d₆ is the deuterium labeled Sulindac sulfone (HY-B1787). Sulindac sulfone is an mTORC1 pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research ^[1].

HY-N0112S

Dihydromyricetin-d4

Dihydromyricetin-d₄ (Ampelopsin-d₄) is deuterium labeled Dihydromyricetin. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-W765245

Rapamycin-13C,d3-1
Rapamycin- ¹³C,d₃-1 (Sirolimus- ¹³C,d₃-1) is the deuterium labeled and ¹³C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10681S

Gedatolisib-d8
Gedatolisib-d₈ (PKI-587-d₈) is the deuterium labeled Gedatolisib (HY-10681). Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 ^[1] .

Cat. No.	Product Name		Classification

HY-176947

Demethyl-sapanisertib-C2-amide-PEG7-C2-N3		Azide
Demethyl-sapanisertib-C2-amide-PEG7-C2-N3 (Compound 10c) is an azide group linker used for coupling, which can be employed in the synthesis of "Rapa-Link" compounds, such as M-1111 (HY-176948), an mTOR inhibitor ^[1].

Cat. No.	Product Name		Classification

HY-153493A

PF-04523655 sodium		siRNAs siRNA drugs
PF-04523655 sodium is a siRNA directed against RTP801 gene. RTP801 sodium is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

HY-153493

PF-04523655		siRNAs siRNA drugs
PF-04523655 is a siRNA directed against RTP801 gene. RTP801 is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10219G

Rapamycin Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Infection Cancer
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of *mTORC1* ^[1]. Rapamycin is an autophagy activator, an immunosuppressant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

mTORC1

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products